Kuhnil to acquire exclusive license for a super antibiotic.

Published: 2005-08-12 06:58:00

Updated: 2005-08-12 06:58:00

Kuhnil made an exclusive distribution agreement for Cubicin, a super antibiotic, even sensitive to MRSA (methicillin-resistant Staphylococcus aureus), with Cubist Inc., located in Boston, U.S.A on July 14.

Cubist Inc. reported in its 2Q of 2005 financial statement about the nomination of Kuhni...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK